Do analysts prefer SGMO or CELZ?

Sangamo Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher possible upside, equities research analysts clearly believe Sangamo Therapeutics is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75 Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate CELZ or LTRN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CELZ or LTRN more profitable?

Creative Medical Technology's return on equity of -86.52% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Creative Medical Technology N/A -86.52% -81.96% Lantern Pharma N/A -368.02% -148.62%

Does the media refer more to CELZ or LTRN?

In the previous week, Creative Medical Technology had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Creative Medical Technology and 1 mentions for Lantern Pharma. Creative Medical Technology's average media sentiment score of 0.33 beat Lantern Pharma's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Creative Medical Technology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer BYSI or CELZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BeyondSpring 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is BYSI or CELZ more profitable?

BeyondSpring's return on equity of 0.00% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets BeyondSpring N/A N/A -28.88% Creative Medical Technology N/A -86.52% -81.96%

Do analysts recommend GNTA or CELZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genenta Science 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, GNTA or CELZ?

Creative Medical Technology has higher revenue and earnings than Genenta Science. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genenta Science N/A N/A -$7.39M N/A N/A Creative Medical Technology $10K 797.39 -$5.99M -$2.07 N/A

Is GNTA or CELZ more profitable?

Genenta Science's return on equity of 0.00% beat Creative Medical Technology's return on equity. Company Net Margins Return on Equity Return on Assets Genenta Science N/A N/A N/A Creative Medical Technology N/A -86.52% -81.96%

Do analysts prefer KYNB or CELZ?

Kyntra Bio presently has a consensus price target of $32.50, suggesting a potential upside of 307.27%. Given Kyntra Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Kyntra Bio is more favorable than Creative Medical Technology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60 Creative Medical Technology 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media favor KYNB or CELZ?

In the previous week, Kyntra Bio had 3 more articles in the media than Creative Medical Technology. MarketBeat recorded 6 mentions for Kyntra Bio and 3 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 0.33 beat Kyntra Bio's score of -0.70 indicating that Creative Medical Technology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kyntra Bio 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Creative Medical Technology 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Creative Medical Technology (CELZ) Competitors

$1.21 -0.10 (-7.63%)

Closing price 08/24/2026 04:00 PM Eastern

Extended Trading

$1.27 +0.06 (+5.29%)

As of 08/24/2026 07:21 PM Eastern

Compare

CELZ vs. SGMO, LTRN, BYSI, GNTA, and KYNB

Should you buy Creative Medical Technology stock or one of its competitors? Creative Medical Technology's main competitors and comparable companies include Sangamo Therapeutics (SGMO), Lantern Pharma (LTRN), BeyondSpring (BYSI), Genenta Science (GNTA), and Kyntra Bio (KYNB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Creative Medical Technology compare to Sangamo Therapeutics?

Sangamo Therapeutics (NASDAQ:SGMO) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Creative Medical Technology has lower revenue, but higher earnings than Sangamo Therapeutics. Creative Medical Technology is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
Creative Medical Technology	$10K	797.39	-$5.99M	-$2.07	N/A

56.9% of Sangamo Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 4.1% of Sangamo Therapeutics shares are held by company insiders. Comparatively, 1.0% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Creative Medical Technology has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Creative Medical Technology's return on equity of -86.52% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
Creative Medical Technology	N/A	-86.52%	-81.96%

In the previous week, Creative Medical Technology had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for Creative Medical Technology and 0 mentions for Sangamo Therapeutics. Creative Medical Technology's average media sentiment score of 0.33 beat Sangamo Therapeutics' score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
Creative Medical Technology	Neutral

Sangamo Therapeutics has a beta of 1.3, indicating that its stock price is 30% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market.

Sangamo Therapeutics presently has a consensus price target of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher possible upside, equities research analysts clearly believe Sangamo Therapeutics is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Creative Medical Technology beats Sangamo Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Creative Medical Technology compare to Lantern Pharma?

Creative Medical Technology (NASDAQ:CELZ) and Lantern Pharma (NASDAQ:LTRN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Creative Medical Technology had 2 more articles in the media than Lantern Pharma. MarketBeat recorded 3 mentions for Creative Medical Technology and 1 mentions for Lantern Pharma. Creative Medical Technology's average media sentiment score of 0.33 beat Lantern Pharma's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Creative Medical Technology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lantern Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Creative Medical Technology has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

Creative Medical Technology has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Creative Medical Technology	$10K	797.39	-$5.99M	-$2.07	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A

Creative Medical Technology's return on equity of -86.52% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Creative Medical Technology	N/A	-86.52%	-81.96%
Lantern Pharma	N/A	-368.02%	-148.62%

1.4% of Creative Medical Technology shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 1.0% of Creative Medical Technology shares are held by insiders. Comparatively, 8.5% of Lantern Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Creative Medical Technology beats Lantern Pharma on 9 of the 13 factors compared between the two stocks.

How does Creative Medical Technology compare to BeyondSpring?

BeyondSpring (NASDAQ:BYSI) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

BeyondSpring has higher revenue and earnings than Creative Medical Technology. BeyondSpring is trading at a lower price-to-earnings ratio than Creative Medical Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeyondSpring	$1.75M	16.66	-$1.01M	-$0.12	N/A
Creative Medical Technology	$10K	797.39	-$5.99M	-$2.07	N/A

In the previous week, Creative Medical Technology had 3 more articles in the media than BeyondSpring. MarketBeat recorded 3 mentions for Creative Medical Technology and 0 mentions for BeyondSpring. Creative Medical Technology's average media sentiment score of 0.33 beat BeyondSpring's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
BeyondSpring	Neutral
Creative Medical Technology	Neutral

BeyondSpring has a beta of 0.48, indicating that its share price is 52% less volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.95, indicating that its share price is 95% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeyondSpring	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

40.3% of BeyondSpring shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 29.3% of BeyondSpring shares are held by insiders. Comparatively, 1.0% of Creative Medical Technology shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BeyondSpring's return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeyondSpring	N/A	N/A	-28.88%
Creative Medical Technology	N/A	-86.52%	-81.96%

Summary

BeyondSpring and Creative Medical Technology tied by winning 7 of the 14 factors compared between the two stocks.

How does Creative Medical Technology compare to Genenta Science?

Genenta Science (NASDAQ:GNTA) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, risk, valuation, profitability and institutional ownership.

15.1% of Genenta Science shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 29.0% of Genenta Science shares are held by company insiders. Comparatively, 1.0% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Creative Medical Technology had 3 more articles in the media than Genenta Science. MarketBeat recorded 3 mentions for Creative Medical Technology and 0 mentions for Genenta Science. Creative Medical Technology's average media sentiment score of 0.33 beat Genenta Science's score of 0.00 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Overall Sentiment
Genenta Science	Neutral
Creative Medical Technology	Neutral

Creative Medical Technology has higher revenue and earnings than Genenta Science.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genenta Science	N/A	N/A	-$7.39M	N/A	N/A
Creative Medical Technology	$10K	797.39	-$5.99M	-$2.07	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genenta Science	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Genenta Science has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.95, suggesting that its stock price is 95% more volatile than the broader market.

Genenta Science's return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genenta Science	N/A	N/A	N/A
Creative Medical Technology	N/A	-86.52%	-81.96%

Summary

Creative Medical Technology beats Genenta Science on 7 of the 11 factors compared between the two stocks.

How does Creative Medical Technology compare to Kyntra Bio?

Kyntra Bio (NASDAQ:KYNB) and Creative Medical Technology (NASDAQ:CELZ) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership, profitability and media sentiment.

Kyntra Bio has a net margin of 2,199.13% compared to Creative Medical Technology's net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat Creative Medical Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kyntra Bio	2,199.13%	N/A	-47.27%
Creative Medical Technology	N/A	-86.52%	-81.96%

In the previous week, Kyntra Bio had 3 more articles in the media than Creative Medical Technology. MarketBeat recorded 6 mentions for Kyntra Bio and 3 mentions for Creative Medical Technology. Creative Medical Technology's average media sentiment score of 0.33 beat Kyntra Bio's score of -0.70 indicating that Creative Medical Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kyntra Bio	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Creative Medical Technology	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Kyntra Bio has higher revenue and earnings than Creative Medical Technology. Creative Medical Technology is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kyntra Bio	$6.44M	5.02	$183.45M	$45.30	0.18
Creative Medical Technology	$10K	797.39	-$5.99M	-$2.07	N/A

Kyntra Bio presently has a consensus price target of $32.50, suggesting a potential upside of 307.27%. Given Kyntra Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Kyntra Bio is more favorable than Creative Medical Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Creative Medical Technology	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 1.4% of Creative Medical Technology shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by company insiders. Comparatively, 1.0% of Creative Medical Technology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Kyntra Bio has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market. Comparatively, Creative Medical Technology has a beta of 1.95, indicating that its stock price is 95% more volatile than the broader market.

Summary

Kyntra Bio beats Creative Medical Technology on 14 of the 17 factors compared between the two stocks.

Get Creative Medical Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELZ vs. The Competition

Export

Metric	Creative Medical Technology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.64M	$4.01B	$7.36B	$12.81B
Dividend Yield	N/A	3.64%	2.54%	10.78%
P/E Ratio	-0.58	11.69	270.56	24.05
Price / Sales	797.39	1,415.32	639.68	105.23
Price / Cash	N/A	44.94	29.03	36.89
Price / Book	0.59	17.26	11.18	6.40
Net Income	-$5.99M	-$22.72M	$3.46B	$347.95M
7 Day Performance	12.04%	2.51%	1.73%	1.49%
1 Month Performance	49.38%	9.80%	7.33%	5.15%
1 Year Performance	-62.07%	57.43%	26.11%	17.01%

Creative Medical Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELZ Creative Medical Technology	1.757 of 5 stars	$1.21 -7.6%	N/A	-62.1%	$8.64M	$10K	N/A	5	Analyst Upgrade
SGMO Sangamo Therapeutics	1.0792 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480
LTRN Lantern Pharma	0.1619 of 5 stars	$2.36 -5.1%	N/A	-53.2%	$30.20M	N/A	N/A	20	Gap Down
BYSI BeyondSpring	0.0369 of 5 stars	$0.72 flat	N/A	-59.7%	$29.69M	$1.75M	N/A	80	Gap Down
GNTA Genenta Science	0.4493 of 5 stars	$1.25 +2.5%	N/A	-67.2%	$29.49M	N/A	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELZ) was last updated on 8/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Creative Medical Technology (CELZ) Competitors

CELZ vs. SGMO, LTRN, BYSI, GNTA, and KYNB

How does Creative Medical Technology compare to Sangamo Therapeutics?

Summary

How does Creative Medical Technology compare to Lantern Pharma?

Summary

How does Creative Medical Technology compare to BeyondSpring?

Summary

How does Creative Medical Technology compare to Genenta Science?

Summary

How does Creative Medical Technology compare to Kyntra Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Creative Medical Technology (CELZ) Competitors

CELZ vs. SGMO, LTRN, BYSI, GNTA, and KYNB

How does Creative Medical Technology compare to Sangamo Therapeutics?

Which has better valuation & earnings, SGMO or CELZ?

Do insiders and institutionals hold more shares of SGMO or CELZ?

Is SGMO or CELZ more profitable?

Does the media favor SGMO or CELZ?

Which has more volatility and risk, SGMO or CELZ?

Do analysts prefer SGMO or CELZ?

Summary

How does Creative Medical Technology compare to Lantern Pharma?

Does the media refer more to CELZ or LTRN?

Which has more volatility & risk, CELZ or LTRN?

Which has preferable valuation and earnings, CELZ or LTRN?

Is CELZ or LTRN more profitable?

Do insiders & institutionals have more ownership in CELZ or LTRN?

Do analysts rate CELZ or LTRN?

Summary

How does Creative Medical Technology compare to BeyondSpring?

Which has higher earnings and valuation, BYSI or CELZ?

Does the media refer more to BYSI or CELZ?

Which has more volatility & risk, BYSI or CELZ?

Do analysts prefer BYSI or CELZ?

Do insiders and institutionals hold more shares of BYSI or CELZ?

Is BYSI or CELZ more profitable?

Summary

How does Creative Medical Technology compare to Genenta Science?

Do institutionals and insiders have more ownership in GNTA or CELZ?

Does the media refer more to GNTA or CELZ?

Which has stronger earnings and valuation, GNTA or CELZ?

Do analysts recommend GNTA or CELZ?

Which has more volatility and risk, GNTA or CELZ?

Is GNTA or CELZ more profitable?

Summary

How does Creative Medical Technology compare to Kyntra Bio?

Is KYNB or CELZ more profitable?

Does the media favor KYNB or CELZ?

Which has better valuation & earnings, KYNB or CELZ?

Do analysts prefer KYNB or CELZ?

Do insiders and institutionals hold more shares of KYNB or CELZ?

Which has more volatility and risk, KYNB or CELZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELZ vs. The Competition

Creative Medical Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools